Breaking News Instant updates and real-time market news.

ACST

Acasti Pharma

$1.95

0.06 (3.17%)

08:47
09/30/19
09/30
08:47
09/30/19
08:47

Acasti Pharma 'on track' to report topline results for TRILOGY 1 in December

Acasti Pharma reported additional milestones reached and provided a business update on its clinical trials. COO and CSO Pierre Lemieux commented, "Our TRILOGY Phase 3 trials in patients with severe hypertriglyceridemia continue to progress, and we remain on track to report topline TRILOGY 1 results in December 2019, and topline TRILOGY 2 results in January 2020. Importantly, both of our TRILOGY studies have achieved 100% patient randomization, and nearly 80% of the patients in both studies combined have now completed their 6-month plan. It is important to note that data clean up is approximately 90% complete in TRILOGY 1, bringing us closer to database lock. We have also progressed TRILOGY 2 and anticipate database lock as planned in January 2020." Jan D'Alvise, president and CEO of Acasti, further noted, "Given the positive results we saw from our Phase 2 trials in a total of 675 patients, we eagerly await the completion of the results from our two TRILOGY clinical studies. It is also important to note: patients enrolled in the Phase 3 TRILOGY trials have higher baseline triglyceride levels versus our Phase 2 studies, where most had baseline triglycerides significantly below 500 mg/dl; patients randomized to CaPre in the Phase 3 TRILOGY trials all received 4 grams per day and will remain on drug for 6 months, while our Phase 2 studies included patients receiving a range of doses from 1 gram, 2 grams and 4 grams per day for only 8 to 12 weeks with a favorable dose response; the Phase 2 trials also indicated that CaPre may have a positive effect on other major lipid markers such as VLDL, LDL-C, and HDL-C, as well as HbA1c in patients with diabetes." As previously disclosed, topline results will include a readout of the primary endpoint, which is intended to show CaPre's overall impact on lowering triglycerides after 12 weeks compared to placebo. The placebo used in the TRILOGY trials is cornstarch, which is inert, and consequently is expected to have a neutral effect on key biomarkers of patients in the placebo group. The TRILOGY studies are designed to provide at least 90% statistical power to detect a difference of at least a 20% decrease from baseline in TGs between CaPre and placebo. The Company has shared the statistical analysis plan for the analysis and reporting of the TRILOGY results with the FDA, and expects to finalize the SAP prior to final database lock. Subject to any input from the FDA, Acasti is currently planning that the topline TRILOGY results will include the primary endpoint of TG reduction at Week 12 compared to placebo. Safety and tolerability will also be reported. The Company currently expects that topline results will not include any secondary or exploratory endpoints. The important secondary and exploratory endpoint results are expected to follow shortly after the release of the topline results of TRILOGY 2, currently anticipated in late January, 2020. According to the SAP, the primary endpoint must first be positive with statistical significance prior to analyzing the secondary and exploratory endpoints. These endpoints will then be analyzed in the following order: 1) additional TG secondary endpoints, including TG reduction at Week 26, which is intended to show CaPre's persistence of effect, TG reduction in various subgroups to show consistency of effect (such as patients stratified with baseline qualifying TG levels of less than or equal to750 mg/dL vs. greater than750 mg/dL), and a comparison of TG reduction in patients using and not using statins at baseline; 2) Non-HDL-C; 3) VLDL-C; 4) HDL-C; 5) LDL-C and HbA1c. Physician investigators determined if patients with high LDL-C and/or high HbA1c levels at screening needed to be put on standard therapy, and if so, they were stabilized prior to being randomized into TRILOGY. Results for both LDL-C and HbA1c will then require subgroup analyses, which are done by combining diabetic patients and separately patients with high LDL-C from both studies at baseline to reach adequate statistical power to detect a difference if one exists, and therefore potentially show any incremental benefit of CaPre above and beyond the standard of care. Acasti expects that the remaining secondary and exploratory endpoints along with various additional subgroup analyses should be completed before the end of March 2020. In addition to the preliminary topline data, the Company will seek to present the full data set, which will include results for key secondary and exploratory endpoints of interest such as Non-HDL-C, LDL-C, VLDL, HDL-C and HbA1c at key scientific meetings in 2020. The Company will communicate more information in the months ahead on how and when all of the TRILOGY results will be reported once the SAP is finalized.

  • 02

    Oct

  • 10

    Oct

  • 11

    Oct

  • 23

    Oct

  • 24

    Oct

ACST Acasti Pharma
$1.95

0.06 (3.17%)

07/09/19
AGIS
07/09/19
INITIATION
Target $3
AGIS
Buy
Aegis starts 'promising Omega-3 story' Acasti with Buy rating, $3 price target
As previously reported, Aegis analyst Nathan Weinstein initiated Acasti Pharma (ACST) with a Buy rating and $3 price target, telling investors that the company's Omega-3 therapeutic for the treatment of very high triglycerides, called CaPre, has demonstrated "interesting efficacy" in phase 2 study. Several companies have entered or could be close to entering the prescription Omega-3 space, including Amarin (AMRN), but Weinstein points to precedent cases of third and later entrants achieving market success in various therapeutic categories.
07/18/19
OPCO
07/18/19
INITIATION
Target $7
OPCO
Outperform
Acasti Pharma initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leland Gershell started Acasti Pharma with an Outperform rating and $7 price target.
07/18/19
07/18/19
INITIATION
Target $7

Outperform
Oppenheimer bullish on Acasti Pharma, initiates with an Outperform
As previously reported, Oppenheimer analyst Leland Gershell started coverage of Acasti Pharma (ACST) with an Outperform rating and $7 price target. While the analyst notes that Vascepa's prospects to serve a multibillion-dollar sales opportunity have driven significant value appreciation for Amarin (AMRN), he believes Acasti Pharma's potentially best-in-class omega-3 is only months away from pivotal readouts in the very high triglycerides niche, and anticipates a REDUCE-IT-like label expansion can be secured without new outcomes data. With shares trading at just a about $100M EV, Gershell believes Acasti holds "considerable upside" as CaPre approaches commercialization, its advantages are better appreciated, and Vascepa's sales growth continues to impress.
08/29/19
RILY
08/29/19
INITIATION
Target $7.75
RILY
Buy
Acasti Pharma initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico earlier today initiated coverage of Acasti Pharma with a Buy rating and $7.75 price target. The stock in early trading is up 7% to $1.83. The analyst expects positive Phase III results in early Q1 of 2020 for the company's leading drug candidate, CaPre. CaPre is indicated for adverse cardiovascular event risk reduction in patients with elevated levels of certain lipids, a big market of ~80M Americans, Zavoico tells investors in a research note. He believes CaPre could be the best-in-class omega-3 fatty acid drug and could capture a large share of the market. He also expects a capital raise by Acasti or partnership agreement later this year or early in 2020.

TODAY'S FREE FLY STORIES

AGTC

Applied Genetic

$2.76

-0.125 (-4.33%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Conference/Events
Applied Genetic management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 04

    Dec

QGEN

Qiagen

$37.48

0.175 (0.47%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Hot Stocks
Breaking Hot Stocks news story on Qiagen »

Qiagen trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/15/19
11/15
15:16
11/15/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.46

2.48 (1.89%)

15:00
11/15/19
11/15
15:00
11/15/19
15:00
Periodicals
Oklahoma judge cuts J&J payment due in opioid case to $465M, Reuters reports »

An Oklahoma judge has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

EA

Electronic Arts

$97.88

0.34 (0.35%)

14:59
11/15/19
11/15
14:59
11/15/19
14:59
Periodicals
EA, BioWare planning complete revamp of 'Anthem,' Kotaku says »

Video game developer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

F

Ford

$8.95

0.15 (1.70%)

, GM

General Motors

$36.92

0.12 (0.33%)

14:56
11/15/19
11/15
14:56
11/15/19
14:56
Periodicals
States sue EPA for right for stricter emission regulations, Washington Post says »

California, along with 23…

F

Ford

$8.95

0.15 (1.70%)

GM

General Motors

$36.92

0.12 (0.33%)

HMC

Honda

$29.01

0.175 (0.61%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$144.15

1.02 (0.71%)

TSLA

Tesla

$350.80

1.29 (0.37%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.03

0.05 (0.31%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 04

    Feb

MDLZ

Mondelez

$52.71

-0.19 (-0.36%)

14:52
11/15/19
11/15
14:52
11/15/19
14:52
Hot Stocks
Mondelez recalls Cheese Nips in U.S. due to potential presence of plastic pieces »

Mondelez Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLM

Columbia Sportswear

$93.21

-1.28 (-1.35%)

14:50
11/15/19
11/15
14:50
11/15/19
14:50
Conference/Events
Columbia Sportswear participates in a conference call with Wedbush »

Footwear & Apparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

14:47
11/15/19
11/15
14:47
11/15/19
14:47
Conference/Events
Wedbush hardware/component analyst to hold an analyst/industry conference call »

Hardware & Component…

NVS

Novartis

$89.84

0.32 (0.36%)

14:43
11/15/19
11/15
14:43
11/15/19
14:43
Hot Stocks
Novartis receives FDA approval for BLA for Adakveo injection »

The FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ALNA

Allena Pharmaceuticals

$1.61

-0.03 (-1.83%)

14:39
11/15/19
11/15
14:39
11/15/19
14:39
Conference/Events
Wedbush emerging pharma analyst to hold an analyst/industry conference call »

Emerging Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

, CYH

Community Health

$2.95

0.075 (2.61%)

14:38
11/15/19
11/15
14:38
11/15/19
14:38
Hot Stocks
Hospital stocks up after Trump reveals healthcare price transparency proposal »

Shares of several…

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

CYH

Community Health

$2.95

0.075 (2.61%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$142.53

1.36 (0.96%)

THC

Tenet

$29.91

0.44 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.69

2.2 (10.24%)

14:28
11/15/19
11/15
14:28
11/15/19
14:28
Recommendations
Amarin analyst commentary  »

Amarin price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

VIA

Viacom

$26.63

1.32 (5.22%)

, VIAB

Viacom

$23.20

0.72 (3.20%)

14:25
11/15/19
11/15
14:25
11/15/19
14:25
On The Fly
Box Office Battle: 'Ford v Ferrari' seen topping 'Charlie's Angels' this weekend »

Welcome to "Box Office…

VIA

Viacom

$26.63

1.32 (5.22%)

VIAB

Viacom

$23.20

0.72 (3.20%)

FOX

Fox Corp.

$33.85

0.39 (1.17%)

FOXA

Fox Corp.

$34.51

0.29 (0.85%)

T

AT&T

$39.28

0.315 (0.81%)

DIS

Disney

$144.95

-2.24 (-1.52%)

CMCSA

Comcast

$44.61

-0.86 (-1.89%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$9.76

0.41 (4.39%)

LGF.B

Lionsgate

$9.15

0.43 (4.93%)

SNE

Sony

$62.10

0.3 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

AZN

AstraZeneca

$47.18

-0.19 (-0.40%)

14:25
11/15/19
11/15
14:25
11/15/19
14:25
Options
AstraZeneca call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

14:25
11/15/19
11/15
14:25
11/15/19
14:25
General news
Treasury Action: Treasuries remain slightly weaker »

Treasury Action:…

GOOG

Alphabet

$1,328.60

16.41 (1.25%)

, GOOGL

Alphabet Class A

$1,327.62

17.83 (1.36%)

14:20
11/15/19
11/15
14:20
11/15/19
14:20
Hot Stocks
Supreme Court to consider Google appeal of Oracle copyright case »

The U.S. Supreme Court…

GOOG

Alphabet

$1,328.60

16.41 (1.25%)

GOOGL

Alphabet Class A

$1,327.62

17.83 (1.36%)

ORCL

Oracle

$56.42

0.32 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/15/19
11/15
14:17
11/15/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,748.38

-6.33 (-0.36%)

14:16
11/15/19
11/15
14:16
11/15/19
14:16
Periodicals
John Lynch leaving Amazon Studios, Variety reports »

Amazon Studios head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/15/19
11/15
14:16
11/15/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$243.22

2.82 (1.17%)

14:12
11/15/19
11/15
14:12
11/15/19
14:12
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$74.07

0.215 (0.29%)

14:05
11/15/19
11/15
14:05
11/15/19
14:05
Hot Stocks
Citi reports October credit loss 2.61% vs. 2.61% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

GOOG

Alphabet

$1,326.95

14.76 (1.12%)

, GOOGL

Alphabet Class A

$1,325.85

16.06 (1.23%)

13:55
11/15/19
11/15
13:55
11/15/19
13:55
Periodicals
Google cancels weekly TGIF meetings, CNBC reports »

Google is dropping TGIF,…

GOOG

Alphabet

$1,326.95

14.76 (1.12%)

GOOGL

Alphabet Class A

$1,325.85

16.06 (1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
11/15/19
11/15
13:55
11/15/19
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.